ClinicalTrials.gg
Not yet recruitingNCT07720167Updated Nov 10, 2026

Cemiplimab for Clinical Stage I, 2-3.9cm, Non-Small Cell Lung Cancer

A Phase 2 interventional study of Cemiplimab and Pemetrexed (1) in Non-Small Cell Lung Cancer, sponsored by Medical University of South Carolina. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Medical University of South Carolina · Phase 2, Interventional, and Treatment

How we know

Updated Nov 10, 2026Start date movedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
38
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung — 19 open to participants now, 23 under way, 4 of them phase 3. cemiplimab · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
20th of 30
38 · median 62
Started
2027
with 2 others
Phase 2
19 of 30
13 open now
Primary completion
2035-08
later than 22 of 22 live
Registered
27th of 30
by date

Among the 30 studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung, this one is the 20th largest by planned enrollment, is one of 3 that started in 2027, is one of 19 in phase 2, reaches primary completion later than 22 of the 22 other live ones, and was the 27th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

19 of the 30 studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 19 open studies →

About cemiplimab

cemiplimab: first FDA approval 2018 (LIBTAYO), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The study will investigate the role of cemiplimab in combination with platinum doublet chemotherapy in stage I resectable non-small cell lung cancer (NSCLC). Sub-4cm NSCLC tumors are highly lethal malignancies, yet no therapies are used in these patients to improve chances of survival with surgery alone. Here will be examined the ability of 3 cycles of cemiplimab-chemotherapy to induce pathologic complete responses to treatment.

03

Conditions studied

  • Non-Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  1. Participants must have proven NSCLC, clinically staged cT1c or T2a, clinically node-negative (no bronchoscopy is required for screening) using AJCC 9th Edition.
  2. Participants must have an SUVmax >6.2 on standard of care staging PET scan, and/or histology must be consistent with moderate/poorly/or undifferentiated NSCLC.
  3. Participants must have pulmonary function study capable of tolerating the proposed lung resection according to the surgeon. This will require post-operative predicted forced expiratory volume (FEV) 1 and diffusing capacity of the lungs for carbon monoxide (DLCO) greater than 40%.
  4. Participants must be deemed a surgical candidate with adequate organ function, documented in the electronic medical record (EMR).
  5. Participants must have Performance status 0-1.
  6. Participants must have a signed and dated IRB approved written consent form before the performance of any protocol related procedures that are not part of the normal participant care.
  7. Participants must be aged >18 years old.

Exclusion Criteria:

  1. Participants must have no known ALK driver mutations
  2. Participants must have no known EGFR mutations.
  3. Participants must not have known or suspected active disease requiring systemic treatment within the past two years. Participants with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.
  4. Participants must not have any condition treated with chemotherapy or other cancer therapy, including , anti-PD-L1, anti-PDL-2, or anti-CTLA-4 antibody (or any other antibody targeting T-cell co-regulatory pathways).
  5. Prior active within the previous 3 years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast.
  6. Participants must not have history of symptomatic interstitial lung disease.
  7. Prisoners or subjects who are involuntarily incarcerated or compulsorily detained for treatment of either a psychiatric or physical (e.g., infectious disease) illness will be excluded from the study.
  8. Participants must not have previous history of bone marrow transplant.
  9. Participants must not have a known allergy, or history of allergy or to study drug or any of the .
  10. Presence of cardiovascular disease, as defined by:

    a) heart failure classifications of Class II, III, or IV; or myocardial infarction, or acute coronary syndrome within 12 months of first dose of study medication; or b) or stroke within 1 year.

  11. Any condition that requires ongoing/continuous or immunosuppressive therapy (>10 mg prednisone/day or anti-inflammatory equivalent) within 1 week prior to the first dose of study medication. Participants who require a brief course of steroids (up to 2 days in the week before enrollment) or physiologic replacement are not excluded.
  12. Any infection requiring hospitalization or treatment with IV anti-infectives within 2 weeks of first dose of study medication.
  13. Known infection with , or infection, diagnosis of immunodeficiency, and/or tuberculosis (active or latent).
  14. Exclusions relating to vaccines:

    a) Receipt of a within 4 weeks of start of study medication. b) Receipt of COVID-19 vaccination within 1 week of planned start of study medication or for which the planned COVID-19 vaccinations would not be completed 1 week prior to start of study medication.

  15. Exclusions and information relating to pregnancy/:

    1. * and men** who are unwilling to practice highly effective contraception prior to the initial dose/start of the first treatment, during the study, and for at least 6 months after the last dose. Highly effective contraceptive measures include:

    i. Stable use of combined (estrogen and progestogen containing) hormonal contraception (oral, intravaginal, transdermal) or progestogen-only hormonal contraception (oral, injectable, implantable) associated with inhibition of ovulation initiated 2 or more menstrual cycles prior to screening; ii. Intrauterine device; intrauterine hormone-releasing system; iii. Bilateral tubal occlusion/ligation; iv. Vasectomized partner (provided that the male vasectomized partner is the sole sexual partner of the WOCBP study participant and that the vasectomized partner has obtained medical assessment of surgical success for the procedure); and/or v. Sexual abstinence†,‡.

    Note: Pregnancy testing and contraception are required for WOCBP. Pregnancy testing and contraception are not required for women who are or permanently sterile.

    • WOCBP are defined as women who are fertile following menarche until becoming postmenopausal, unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy, and bilateral oophorectomy.

    A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high FSH level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy. However, in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient to determine the occurrence of a postmenopausal state. The above definitions are according to the CTFG guidance. Pregnancy testing and contraception are not required for women with documented hysterectomy or tubal ligation.

    **Male participants: A male participant will be excluded from the study if that participant does not agree to use condoms or practice sexual abstinence†‡, unless vasectomized, prior to the initial dose/start of study medication, during the study, and for at least 6 months after the last dose. Sperm donation is also prohibited during the same period. Vasectomy success must be confirmed by semen analysis.

    †Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study drugs. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the participant.

    • Periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides only, and lactational amenorrhea method are not acceptable methods of contraception. Female condom and male condom should not be used together.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
38 participants (estimated)

Study arms

  • Experimental
    Cemiplimab+Investigator's choice platinum doublet for clinical stage 1, 2-3.9cm, NSCLC

    Patients will receive carboplatin + pemetrexed/paclitaxel or cisplatin. Followed by surgery. Safety labs and physical exam 3 weeks post-surgery. Long-term follow up.

    Drug: Cemiplimab · Drug: Pemetrexed (1) · Drug: Cisplatin · Drug: Carboplatin · Drug: Paclitaxel

Interventions

  • administered at a dose of 350 mg as an intravenous infusion over 30 minutes

  • DrugPemetrexedStudies of PemetrexedPemetrexed pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    every 21 days for three cycles if adenocarcinoma histology

  • every 21 days for three cycles if not using carboplatin

  • every 21 days for three cycles if not using cisplatin

  • every 21 days for 3 cycles if Squamous cell histology

06

What researchers measure

Primary outcomes

  1. Frequency and percentage of patients with a pathologic complete response (pCR) rate

    defined as the rate of ypT0N0 stage disease based on American Joint Committee on Cancer (AJCC) and Union for International Cancer Control (UICC) staging systems with 0 being the minimum and better while higher numbers mean worse

    Time frame: 3 weeks post-surgery +/- 1 week

Secondary outcomes

  1. Frequency and grade of adverse events and serious adverse events

    based on CTCAE v5.0

    Time frame: At the start of Cycle 1 (each cycle is 21 days) to 3 weeks post surgery

  2. Relapse-free survival

    defined as the time interval from date of surgery until disease recurrence or death due to any cause.

    Time frame: from surgery to 5 years post surgery

  3. Overall survival

    defined as the time interval from C1D1 of treatment with the investigational intervention to death due to any cause.

    Time frame: At the start of Cycle 1 (each cycle is 21 days) to 5 years post surgery

  4. frequency and percentage surgical margin status based on residual (R) tumor classification (R0, R1, R2)

    will be summarized by the frequency and percentage of patients classified as R0, R1, and R2 based on residual tumor classification

    Time frame: Within 6 weeks of start of Cycle 3 (each cycle is 21 days)

  5. frequencies and percentages of delayed or cancelled surgeries

    Number and proportion of delayed or cancelled surgeries

    Time frame: Within 6 weeks of start of Cycle 3 (each cycle is 21 days)

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2027; primary completion for Aug 2035, 102 months later.

Of 732 non-industry phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 84. This study's planned 102 months is above that.

Counting every sponsor, half of 1,049 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: start Nov 2026 → Feb 2027, primary completion Nov 2029 → Aug 2035 and completion Nov 2030 → Aug 2036.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2026
First posted
Jul 22, 2026
StartEst.
Feb 1, 2027was Nov 2026
Primary completionEst.
Aug 1, 2035was Nov 2029
CompletionEst.
Aug 1, 2036was Nov 2030
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Nov 1, 2026→Feb 1, 2027
Nov 10, 2026
Primary completion
Nov 1, 2029→Aug 1, 2035
Nov 10, 2026
Study completion
Nov 1, 2030→Aug 1, 2036
Nov 10, 2026
Interventions
Added Drug: Pemetrexed (1)·Drug: Carboplatin·Drug: Paclitaxel; removed Drug: Carboplatin + Pemetrexed/Paclitaxel
Nov 10, 2026
Primary outcomes
1 time frame changed, 1 description edited
What changed in the outcomes
  • Time frameFrequency and percentage of patients with a pathologic complete response (pCR) rate5.5 years → 3 weeks post-surgery +/- 1 week
  • DescriptionFrequency and percentage of patients with a pathologic complete response (pCR) rate: how it is measured was reworded
Nov 10, 2026
Secondary outcomes
5 time frame changed, 4 removed
What changed in the outcomes
  • Time frameFrequency and grade of adverse events and serious adverse events5.5 years → At the start of Cycle 1 (each cycle is 21 days) to 3 weeks post surgery
  • Time frameRelapse-free survival5.5 years → from surgery to 5 years post surgery
  • Time frameOverall survival5.5 years → At the start of Cycle 1 (each cycle is 21 days) to 5 years post surgery
  • Time framefrequency and percentage surgical margin status based on residual (R) tumor classification (R0, R1, R2)5.5 years → Within 6 weeks of start of Cycle 3 (each cycle is 21 days)
  • Time framefrequencies and percentages of delayed or cancelled surgeries5.5 years → Within 6 weeks of start of Cycle 3 (each cycle is 21 days)
  • Removedother outcomesummarized ctDNA, TCR repertoires, and DetermaIO assay IO scoresTime frame: 5.5 years
  • Removedother outcomefrequency and percentage of operative approach (minimally invasive versus open)Time frame: 5.5 years
  • Removedother outcomePost-surgical length of stayTime frame: 5.5 years
  • Removedother outcomefrequencies and percentages of incidence of adverse events within 90 days of and associated with surgeryTime frame: 5.5 years
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Start date Nov 1, 2026→Feb 1, 2027
    Primary completion Nov 1, 2029→Aug 1, 2035
    Study completion Nov 1, 2030→Aug 1, 2036
    Primary outcomes 1 time frame changed, 1 description edited
    What changed in the outcomes
    • Time frameFrequency and percentage of patients with a pathologic complete response (pCR) rate5.5 years → 3 weeks post-surgery +/- 1 week
    • DescriptionFrequency and percentage of patients with a pathologic complete response (pCR) rate: how it is measured was reworded
    Secondary outcomes 5 time frame changed, 4 removed
    What changed in the outcomes
    • Time frameFrequency and grade of adverse events and serious adverse events5.5 years → At the start of Cycle 1 (each cycle is 21 days) to 3 weeks post surgery
    • Time frameRelapse-free survival5.5 years → from surgery to 5 years post surgery
    • Time frameOverall survival5.5 years → At the start of Cycle 1 (each cycle is 21 days) to 5 years post surgery
    • Time framefrequency and percentage surgical margin status based on residual (R) tumor classification (R0, R1, R2)5.5 years → Within 6 weeks of start of Cycle 3 (each cycle is 21 days)
    • Time framefrequencies and percentages of delayed or cancelled surgeries5.5 years → Within 6 weeks of start of Cycle 3 (each cycle is 21 days)
    • Removedother outcomesummarized ctDNA, TCR repertoires, and DetermaIO assay IO scoresTime frame: 5.5 years
    • Removedother outcomefrequency and percentage of operative approach (minimally invasive versus open)Time frame: 5.5 years
    • Removedother outcomePost-surgical length of stayTime frame: 5.5 years
    • Removedother outcomefrequencies and percentages of incidence of adverse events within 90 days of and associated with surgeryTime frame: 5.5 years
    Interventions Added Drug: Pemetrexed (1)·Drug: Carboplatin·Drug: Paclitaxel; removed Drug: Carboplatin + Pemetrexed/Paclitaxel
    + 1 other change: index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07720167
Responsible party
Barry Gibney (Associate Professor, Medical University of South Carolina) — Principal investigator
First posted
Jul 22, 2026
Start date
Feb 1, 2027 (estimated)
Primary completion
Aug 1, 2035 (estimated)
Completion
Aug 1, 2036 (estimated)
Last update
Nov 10, 2026

Study contacts

HCC Clinical Trials Office
Contact
hcc-clinical-trials@musc.edu
843-792-9321

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cemiplimab

Start the discussion